6 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 6 of 6 clinical reviews.
A clinical breakdown of rapamycin (sirolimus) compounding regulations, FDA approval history, label indications, and what patients need to know about legally obtaining compounded sirolimus for off-label use.
A analysis of sirolimus FAERS adverse event reports, FDA label warnings, post-market surveillance findings, and what the data means for off-label longevity use.
A detailed review of every major FDA label change to rapamycin (sirolimus) between 2020 and 2026, including new safety warnings, dosing revisions, and post-market surveillance findings.
A comprehensive clinical and regulatory guide to sirolimus (rapamycin): FDA approval history, patent litigation, current label requirements, and post-market safety data, prepared by the HealthRX.com Editorial Team.
A clinical review of sirolimus regulatory history, current off-label longevity research, next-generation rapalogs in development, and what the FDA pipeline means for patients in 2026.
A comparison of how the FDA and EMA regulate sirolimus (Rapamune), covering approved indications, boxed warnings, post-market surveillance, and why neither agency's approval says anything about off-label longevity use.